Date: 23 June Context and policy issues:
|
|
- Timothy Miller
- 5 years ago
- Views:
Transcription
1 Title: Basiliximab for Immunosuppression During a Calcineurin Inhibitor Holiday in Renal Transplant Patients with Acute Renal Dysfunction: Guidelines for Use and a Clinical and Cost-Effectiveness Review Date: 23 June 2008 Context and policy issues: Patients who receive kidney transplants require immunosuppressive therapy in two phases usually termed induction and maintenance therapy to help prevent acute rejection and the loss of the renal allograft. 1,2 During the induction phase, recipients receive higher doses of several concurrent drugs to induce a partially immunosuppressed state. Immunosuppressant drugs are selected that work at various sites in the cell cycle and have non-overlapping toxic effects. 2 The doses are gradually tapered during the first two to four months after transplantation until maintenance levels are achieved. In addition, many transplant centres include a short course of anti-cd25 monoclonal antibodies (also called IL-2-receptor antagonists) during the induction phase. 2 Anti-CD25 monoclonal antibody agents include daclizumab and basiliximab. These agents block the interleukin-2 receptor on activated T lymphocytes, which impedes the immune cascade that causes acute cellular rejection in solid organ transplantation. 3,4 Most transplant centres use an induction/maintenance immunosuppression regimen consisting of a calcineurin-inhibitor (CNI) drug (cyclosporine or tacrolimus) and an anti-metabolite drug (azathioprine or mycophenolate mofetil), with or without corticosteroids. 1 CNI drugs remain the cornerstone agent of the maintenance immunosuppressive regimen. 1 However, there is increasing concern about CNI-induced nephrotoxicity, which is an important contributor to posttransplant chronic allograft dysfunction. 5 The nephrotoxic properties of CNI drugs may delay renal allograft function, hinder diagnosis of clinical rejection, prolong the need for dialysis and result in poorer long-term outcomes. 3 There is no gold standard protocol for managing acute renal dysfunction after solid organ transplant. 6 Various strategies have been used to reduce CNI-induced nephrotoxicity, including decreasing the dose or eliminating the CNI altogether from the treatment regimen. 5 Mammalian Disclaimer: The Health Technology Inquiry Service (HTIS) is an information service for those involved in planning and providing health care in Canada. HTIS responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. HTIS responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report. Copyright: This report contains CADTH copyright material. It may be copied and used for non-commercial purposes, provided that attribution is given to CADTH. Links: This report may contain links to other information on available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners own terms and conditions.
2 target of rapamycin (mtor) inhibitor agents, including sirolimus and everolimus, are increasingly being used as CNI-sparing substitutes. 5 CNI treatment may also be delayed during the early postoperative period while the patient is covered by the immunosuppressant effects of anti-cd25 monoclonal antibodies that are given during the induction phase. Another treatment strategy for transplant patients experiencing acute renal dysfunction is to introduce a CNI holiday (i.e. withhold CNI for a short period of time) to allow kidney function to return to baseline function. However, there is a risk of acute rejection if CNI drugs are withheld. It has been suggested that basiliximab could be used off label (i.e. outside of the induction phase in the immediate transplantation period) to provide immunosuppression while patients with acute renal dysfunction take a temporary CNI drug holiday to allow kidney function to recover and return to baseline function. 6 A review of the guidelines and the clinical effectiveness of basiliximab for this off label use is necessary. In addition, due to the high cost of basiliximab ($1, per 20 mg dose 7 ) it is important to assess the cost-benefit of the off-label use of this drug. Research question(s): 1. What is the clinical effectiveness of switching patients experiencing acute renal dysfunction as a result of using cyclosporin or tacrolimus to basiliximab post-renal transplantation? 2. What is the cost-effectiveness of switching patients experiencing acute renal dysfunction as a result of using cyclosporin or tacrolimus to basiliximab post-renal transplantation? 3. What are the guidelines for the use of basiliximab in renal transplant patients experiencing acute renal dysfunction as a result of using cyclosporin or tacrolimus? Methods: A limited literature search was conducted on key health technology assessment resources, including OVID Pre-Medline, Medline and Embase, Pubmed, The Cochrane Library (Issue 2, 2008), University of York Centre for Reviews and Dissemination (CRD) databases, ECRI, EuroScan, international HTA agencies, and a focused Internet search. Results include articles published between 2000 and May 2008, and are limited to English language publications only. Filters were applied to limit the retrieval to health technology assessments, systematic reviews, meta-analysis, clinical guidelines, randomized clinical trial (RCT) studies, observational and non-randomized studies, and economic evaluations. HTIS reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews and meta-analyses are presented first. These are followed by economic evaluations, randomized controlled trials, observational studies and evidence-based guidelines. Summary of findings: No relevant health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, economic analyses or clinical practice guidelines were identified regarding the clinical effectiveness or cost-effectiveness of switching patients experiencing acute renal dysfunction caused by CNI drugs (cyclosporin or tacrolimus) to basiliximab post-renal transplantation. One published observational study was identified, as well as an abstract of another observational study. Basiliximab for Immunosuppressive Therapy Post Renal Transplant 2
3 Observational studies A small observational study reported using anti-cd25 monoclonal antibody coverage during a temporary CNI holiday. Cantarovich et al 6 described a case series of 11 patients with solid organ transplants who experienced 15 events of acute renal dysfunction due to CNI nephrotoxicity between one month and 14 years post transplant. Seven patients were heart transplant recipients, two patients had received a liver transplant, one a renal transplant (12 years after a heart transplant) and one had received a simultaneous heart/kidney transplant. Acute renal dysfunction was defined as a 25% increase in baseline serum creatinine. The CNI holiday was implemented and continued until serum creatinine had decreased to baseline. Basiliximab was given to seven patients for the treatment of 11 events of acute renal dysfunction. Basiliximab was given at a dose of 20 mg intravenously, followed by 20 mg four days later, and then 20 mg once every 20 days until CNI drugs were reinstated or replaced by mycophenolate mofetil or sirolimus. The remaining four patients received daclizumab at a dose of 1.5 mg/kg intravenously every seven days until CNI drugs were reinstated or replaced by mycophenolate mofetil or sirolimus. The duration of the CNI holiday ranged from 21 ± 51 days (range 6 to 210). Serum creatinine levels (μmol/l) had increased from a mean baseline of 145 ± 48 to 301 ± 92 (P<0.0001) with CNI drug therapy and they decreased to 143 ± 55 with the CNI holiday. Six patients had CNI therapy reintroduced and had a slight increase (10.6%) in serum creatinine to 155 ± 67 (range 71 to 277) at one week; 160 ± 51 (range 91 to 238) at one month; and 160 ± 72 (range 92 to 269) at three months. The remaining five patients were put on sirolimus or mycophenolate mofetil. No episodes of acute rejection occurred and anti-cd25 antibody drugs were well tolerated, with no adverse events reported. Six patients died from causes deemed unrelated to basiliximab or daclizumab therapy two weeks to seven months after the CNI holiday. The authors concluded that a CNI holiday can be implemented in solid organ transplant patients experiencing acute renal dysfunction, under basiliximab or daclizumab coverage. However, observational data obtained from a case series is considered to be weak scientific evidence and the authors stated that prospective randomized studies are required to confirm preliminary results. Also identified was a brief abstract of an observational study reported by Cantarovich in a newsletter highlighting presentations made at a 2006 scientific symposium on transplantation issues. 8 The abstract reported that 24 heart or liver transplant patients with CNI-induced acute renal dysfunction were managed using prolonged therapy with either basiliximab or daclizumab. CNI drug retirement was implemented in six heart transplant patients for 6 ± 2 months and for 14 ± 9 months in seven liver transplant patients. No episodes of acute rejection were recorded. The author concluded that prolonged anti-cd25 monoclonal antibody therapy may allow a CNI holiday or retirement in heart or liver transplant patients with renal dysfunction. The limitations of this preliminary report are that data have not yet been fully reported and the study has not been published in a peer-reviewed journal. Observational data obtained from a case series are considered to be weak scientific evidence and prospective randomized studies are required to confirm these preliminary results. Conclusions and implications for decision or policy making: We identified only two studies, from the same group of investigators, that have reported using anti-cd25 monoclonal antibodies (basiliximab and daclizumab) outside of the induction period in renal transplant patients experiencing acute renal dysfunction due to CNI drugs, including cyclosporin or tacrolimus. Investigators in the Transplantation Division at the Royal Victoria Hospital in Montreal have reported using basiliximab (or daclizumab) to provide immunosuppression coverage during a Basiliximab for Immunosuppressive Therapy Post Renal Transplant 3
4 calcineurin inhibitor holiday in 11 solid organ transplant patients with acute renal dysfunction. 6 Their preliminary findings suggested that a temporary CNI holiday could be safely implemented without acute rejection in solid organ transplant patients, under immunosuppressant coverage with either basiliximab or daclizumab. A prospective randomized study is required to confirm this initial finding, with attention paid to outcome measures such as acute rejection episodes, renal function, and allograft survival. Cost-benefit analyses are also needed. The same Montreal investigators have also reported the preliminary results of using prolonged anti-cd25 monoclonal antibody therapy during CNI holiday or retirement in 24 heart or liver transplant patients. 8 The full results of this observational study have not yet been published in a peer-reviewed journal. The use of anti-cd25 monoclonal antibodies (basiliximab and daclizumab) has facilitated the development of steroid- and CNI-sparing regimens during the immediate post-transplantation period. However, the off-label use of anti-cd25 monoclonal antibodies outside of the immediate post-transplantation period to allow a temporary drug holiday from nephrotoxic CNI drugs requires further evaluation of long-term outcomes in larger numbers of transplant recipients. At present, extremely limited data are available concerning the clinical effectiveness and safety of this regimen; no economic analyses of the regimen were identified. Since basiliximab is typically administered in the hospital during the peri-transplantation period, it would be covered under hospital drug budgets. Each 20 mg dose of basiliximab costs $1, Other costs to consider for its off-label use include those related to administering the drug intravenously over 20 to 30 minutes in a health care facility equipped and staffed to treat any potential severe hypersensitivity reactions. Prepared by: Catherine Allison, B.Sc.(Pharm), MJ, Writer~Researcher Pharmaceuticals Charlene Argáez, MLIS, Information Specialist Health Technology Inquiry Service htis@cadth.ca Tel: Basiliximab for Immunosuppressive Therapy Post Renal Transplant 4
5 References: 1. Tang IY, Meier-Kriesche HU, Kaplan B. Immunosuppressive strategies to improve outcomes of kidney transplantation. Semin Nephrol 2007;27(4): Leichtman AB. Balancing efficacy and toxicity in kidney-transplant immunosuppression. N Engl J Med 2007;357(25): Available: (accessed 2008 Jun 19). 3. Ahsan N. Induction immunotherapy with IL-2Ra monoclonal antibody in kidney transplantation. Minerva Urol Nefrol 2003;55(1): Simulect (basiliximab). East Hanover (NJ): Novartis Pharmaceuticals Corporation; Available: (accessed 2008 Jun 1). 5. Chang SH, Russ GR, Chadban SJ, Campbell S, McDonald SP. Trends in adult postkidney transplant immunosuppressive use in Australia, Nephrology (Carlton) 2008;13(2): Cantarovich M, Metrakos P, Giannetti N, Cecere R, Barkun J, Tchervenkov J. Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor "holiday" in solid organ transplant patients with acute renal dysfunction. Transplantation 2002;73(7): Pharmaceutical products: price list. Dorval (QC): Novartis Canada; CNI sparing strategies: temporary time-out or permanent pasture? In: Highlights from Roche Transforum 2006: focus on the patient's success. Valencia, Spain: Roche; Available: (accessed 2008 May 29). Basiliximab for Immunosuppressive Therapy Post Renal Transplant 5
Title: Parenteral Iron Therapy for Anemia: A Clinical and Cost-Effectiveness Review
Title: Parenteral Iron Therapy for Anemia: A Clinical and Cost-Effectiveness Review Date: 14 February 2008 Context and policy issues: Anemia is a complication of chronic diseases and commonly occurs in
More informationTITLE: Probenecid Dosing When Given with Cefazolin: Guidelines and Clinical Effectiveness
TITLE: Probenecid Dosing When Given with Cefazolin: Guidelines and Clinical Effectiveness DATE: 21 November 2008 RESEARCH QUESTIONS: 1. What is the evidence for the clinical effectiveness of the 1g dose
More informationTITLE: Naltrexone for the Treatment of Alcohol Dependence in Individuals with Co- Dependencies: A Review of the Clinical Effectiveness
TITLE: Naltrexone for the Treatment of Alcohol Dependence in Individuals with Co- Dependencies: A Review of the Clinical Effectiveness DATE: 08 October 2009 CONTEXT AND POLICY ISSUES: Poly-drug abuse is
More informationTITLE: Dose of Electrical Current for Biphasic Defibrillators for Synchronous Cardioversion in Patients with Tachyarrhythmia: Guidelines
TITLE: Dose of Electrical Current for Biphasic Defibrillators for Synchronous Cardioversion in Patients with Tachyarrhythmia: Guidelines DATE: 5 May 2009 RESEARCH QUESTION: What recommendations exist for
More informationTitle: Re-using the Canister Portion of Metered Dose Inhalers in a Hospital Setting: Clinical Review of Safety, Cost-Effectiveness and Guidelines
Title: Re-using the Canister Portion of Metered Dose Inhalers in a Hospital Setting: Clinical Review of Safety, Cost-Effectiveness and Guidelines Date: 16 June 2008 Context and policy issues: A metered
More informationTitle: Scoop Stretcher for Restriction of Spinal Motion: Clinical Effectiveness
Title: Scoop Stretcher for Restriction of Spinal Motion: Clinical Effectiveness Date: 28 May 2008 Research question: What is the evidence for the clinical effectiveness of a scoop stretcher to restrict
More informationDATE: 17 July 2012 CONTEXT AND POLICY ISSUES
TITLE: Sterile Pre-filled Saline Syringes for Acute Care Patients: A Review of Clinical Evidence, Cost-effectiveness, Evidence-based Guidelines, and Safety DATE: 17 July 2012 CONTEXT AND POLICY ISSUES
More informationTITLE: Patient-Controlled Analgesia for Acute Injury Transfers: A Review of the Clinical Effectiveness, Safety, and Guidelines
TITLE: Patient-Controlled Analgesia for Acute Injury Transfers: A Review of the Clinical Effectiveness, Safety, and Guidelines DATE: 11 August 2014 CONTEXT AND POLICY ISSUES Patient-controlled analgesia
More informationTITLE: Use of Bupropion in Patients with Depression and the Associated Risk of Seizures: Safety
TITLE: Use of Bupropion in Patients with Depression and the Associated Risk of Seizures: Safety DATE: 1 April 2010 CONTEXT AND POLICY ISSUES: The prevalence of epilepsy ranges from 0.5% to 1%, 1,2 and
More informationDATE: 09 December 2009 CONTEXT AND POLICY ISSUES:
TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 09 December 2009 CONTEXT AND POLICY
More informationTITLE: Closed Catheter Systems for Prevention of Urinary Tract Infections: A Review of the Clinical Effectiveness
TITLE: Closed Catheter Systems for Prevention of Urinary Tract Infections: A Review of the Clinical Effectiveness DATE: 24 November 2008 CONTEXT AND POLICY ISSUES: Urinary tract infections (UTI) are the
More informationTITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations
TITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations DATE: 29 September 2010 CONTEXT AND POLICY ISSUES: Atrial fibrillation (AF) is the irregular, rapid beating of the
More informationTITLE: Vacuum Boards for Spinal Motion Restriction: Clinical Effectiveness
TITLE: Vacuum Boards for Spinal Motion Restriction: Clinical Effectiveness DATE: 14 October 2008 RESEARCH QUESTION: What are the clinical benefits and harms of using vacuum boards for spinal motion restriction?
More informationTITLE: Proton Pump Inhibitors (PPIs) in Renal Transplant Patients: Evidence for PPI of Choice
TITLE: Proton Pump Inhibitors (PPIs) in Renal Transplant Patients: Evidence for PPI of Choice DATE: 25 August 2008 CONTEXT AND POLICY ISSUES: Gastrointestinal (GI) complications including gastroduodenal
More informationTitle: Elective Endovascular Abdominal Aortic Aneurism Repair versus Open Surgery: A Clinical and Cost Effectiveness Review
Title: Elective Endovascular Abdominal Aortic Aneurism Repair versus Open Surgery: A Clinical and Cost Effectiveness Review Date: 07 April 2008 Context and policy issues: Abdominal aortic aneurism (AAA)
More informationTITLE: Hyperbaric Oxygen Therapy for Autism: A Review of the Clinical and Cost- Effectiveness
TITLE: Hyperbaric Oxygen Therapy for Autism: A Review of the Clinical and Cost- Effectiveness DATE: 19 November 2009 CONTEXT AND POLICY ISSUES: Autism is a pervasive developmental disorder characterized
More informationTITLE: Critical Incident Stress Debriefing for First Responders: A Review of the Clinical Benefit and Harm
TITLE: Critical Incident Stress Debriefing for First Responders: A Review of the Clinical Benefit and Harm DATE: 12 February 2010 CONTEXT AND POLICY ISSUES: Critical incident stress debriefing (CISD) is
More informationTITLE: Discontinuation of Benzodiazepines and Other Sedative-Hypnotic Sleep Medication in Hospitalized Patients: Clinical Evidence and Guidelines
TITLE: Discontinuation of Benzodiazepines and Other Sedative-Hypnotic Sleep Medication in Hospitalized Patients: Clinical Evidence and Guidelines DATE: 25 September 2015 RESEARCH QUESTIONS 1. What is the
More informationTitle: Shortened Dental Arch and Restorative Therapies: Evidence for Functional Dentition
Title: Shortened Dental Arch and Restorative Therapies: Evidence for Functional Dentition Date: 15 May 2008 Context and policy issues: For patients who lose teeth due to various reasons, a fundamental
More informationTITLE: Australian Sheepskins for the Management of Pressure Ulcers: A Review of the Clinical-Effectiveness, Cost-Effectiveness, and Guidelines
TITLE: Australian Sheepskins for the Management of Pressure Ulcers: A Review of the Clinical-Effectiveness, Cost-Effectiveness, and Guidelines DATE: 21 July 2009 CONTEXT AND POLICY ISSUES: Pressure ulcers,
More informationTITLE: Memantine in Combination with Cholinesterase Inhibitors for Alzheimer s Disease: Clinical Effectiveness
TITLE: Memantine in Combination with Cholinesterase Inhibitors for Alzheimer s Disease: Clinical Effectiveness DATE: 30 October 2008 RESEARCH QUESTION: What is the evidence for using memantine in combination
More informationEmerging Drug List EVEROLIMUS
Generic (Trade Name): Manufacturer: Everolimus (Certican ) Novartis Pharmaceuticals NO. 57 MAY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence: For use with cyclosporine
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More informationTITLE: Montelukast for Sleep Apnea: A Review of the Clinical Effectiveness, Cost Effectiveness, and Guidelines
TITLE: Montelukast for Sleep Apnea: A Review of the Clinical Effectiveness, Cost Effectiveness, and Guidelines DATE: 17 January 2014 CONTEXT AND POLICY ISSUES Obstructive sleep apnea (OSA) is a common
More informationSignificance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis
Significance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis Hatem Ali 1,2, Atif Mohiuddin 2,3, Ajay Sharma 2,3, Mohsen El Kosi 2,4 and Ahmed Halawa
More informationOUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes
nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin
More informationDATE: 04 April 2012 CONTEXT AND POLICY ISSUES
TITLE: Procedure Site Bleeding Complications Following Percutaneous Coronary Interventions or Angioplasty: A Review of Clinical Evidence and Guidelines DATE: 04 April 2012 CONTEXT AND POLICY ISSUES Percutaneous
More informationTITLE: Hyperbaric Oxygen Therapy for Adults with Mental Illness: A Review of the Clinical Effectiveness
TITLE: Hyperbaric Oxygen Therapy for Adults with Mental Illness: A Review of the Clinical Effectiveness DATE: 27 August 2014 CONTEXT AND POLICY ISSUES Mental illness, including major depressive episode,
More informationPharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents
BUMC Proceedings 1999;12:110-112 Pharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents CHERYLE GURK-TURNER, RPH Department of Pharmacy Services, BUMC wo mouse/human
More informationTITLE: Type of Thermometer for Inpatients: Clinical-Effectiveness and Guidelines
TITLE: Type of Thermometer for Inpatients: Clinical-Effectiveness and Guidelines DATE: 28 May 2009 RESEARCH QUESTIONS: 1. What is the clinical-effectiveness of tympanic, temporal, oral, and rectal thermometers
More informationTITLE: Dental Loupes for Dental Procedures: A Review of the Clinical and Cost- Effectiveness
TITLE: Dental Loupes for Dental Procedures: A Review of the Clinical and Cost- Effectiveness DATE: 08 October 2008 CONTEXT AND POLICY ISSUES: The use of magnification in dentistry is expanding rapidly.
More informationCADTH RAPID RESPONSE REPORT: REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer: Clinical Effectiveness
CADTH RAPID RESPONSE REPORT: REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer: Clinical Effectiveness Service Line: Rapid Response Service Version: 1.0 Publication Date: August
More informationImmunosuppression: evolution in practice and trends,
American Journal of Transplantation 25; 5 (Part 2): 874 886 Blackwell Munksgaard Blackwell Munksgaard 25 Immunosuppression: evolution in practice and trends, 1993 23 Ron Shapiro a,, James B. Young b, Edgar
More information("T-Lymphocytes, Regulatory"[Mesh]) AND "Immunosuppression"[Mesh] ("T-Lymphocytes, Regulatory"[Mesh]) AND "Immunosuppressive Agents"[Mesh]
SEARCH STRATEGY PubMed: ("T-Lymphocytes, Regulatory"[Mesh]) AND "Immunosuppression"[Mesh] ("T-Lymphocytes, Regulatory"[Mesh]) AND "Immunosuppressive Agents"[Mesh] ("T-Lymphocytes, Regulatory"[Mesh]) AND
More informationTITLE: Delivery of Electroconvulsive Therapy in Non-Hospital Settings: A Review of the Safety and Guidelines
TITLE: Delivery of Electroconvulsive Therapy in Non-Hospital Settings: A Review of the Safety and Guidelines DATE: 08 May 2014 CONTEXT AND POLICY ISSUES Electroconvulsive therapy (ECT) is a treatment that
More informationIntruduction PSI MODE OF ACTION AND PHARMACOKINETICS
Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University
More informationTitle: Ultrasound for Breast Cancer Screening: Clinical Effectiveness. Date: 4 January Context and policy issues:
Title: Ultrasound for Breast Cancer Screening: Clinical Effectiveness Date: 4 January 2008 Context and policy issues: It is estimated that 22,300 women will be diagnosed with breast cancer and approximately
More informationTechnology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta482
Immunosuppressive e therapy for kidney transplant in children and young people Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta482 NICE 2018. All rights reserved. Subject
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors
More informationTITLE: Chiropractic Interventions for Acute or Chronic Lower Back Pain in Adults: A Review of the Clinical and Cost-Effectiveness
TITLE: Chiropractic Interventions for Acute or Chronic Lower Back Pain in Adults: A Review of the Clinical and Cost-Effectiveness DATE: 10 February 2009 CONTEXT AND POLICY ISSUES: Low back pain (LBP) is
More informationLiver Transplant Immunosuppression
Liver Transplant Immunosuppression Michael Daily, MD, MS, FACS Surgical Director, Kidney and Pancreas Transplantation University of Kentucky Medical Center Disclosures No financial disclosures I will be
More informationOBJECTIVES. Phases of Transplantation and Immunosuppression
Transplant and Immunosuppression: Texas Transplant Center April 29, 2017 Regina L. Ramirez, Pharm.D., BCPS PGY1 Pharmacy Residency Program Director Clinical Practice Specialist Solid Organ Transplant and
More informationSerum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant
SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationThe addition of anti-cd25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients GUIDELINES SEARCH STRATEGY
nep_2.fm Page 5 Friday, January 26, 200 6:46 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology120-558 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 20012S1584MiscellaneousCalcineurin
More informationControversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital
Controversies in Renal Transplantation Patrick M. Klem, PharmD, BCPS University of Colorado Hospital The Controversial Questions Are newer immunosuppressants improving patient outcomes? Are corticosteroids
More informationIncreased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation
Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation Gary W Barone 1, Beverley L Ketel 1, Sameh R Abul-Ezz 2, Meredith L Lightfoot 1 1 Department of Surgery
More informationTechnology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481
Immunosuppressive e therapy for kidney transplant in adults Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481 NICE 2018. All rights reserved. Subject to Notice of rights
More informationSurgery in the renal transplant patient
Surgery in the renal transplant patient Prevalence of renal transplants in Australia Prevalence according to State/Territory Overall patient and graft survival following renal transplantation: short term
More informationTITLE: Cognitive Behavioural Therapy for Insomnia in Adults: A Review of the Clinical Effectiveness
TITLE: Cognitive Behavioural Therapy for Insomnia in Adults: A Review of the Clinical Effectiveness DATE: 11 May 2010 CONTEXT AND POLICY ISSUES: Insomnia refers to difficulty initiating and/or maintaining
More informationTITLE: Immediate Osseointegrated Implants for Cancer Patients: A Review of Clinical and Cost-Effectiveness
TITLE: Immediate Osseointegrated Implants for Cancer Patients: A Review of Clinical and Cost-Effectiveness DATE: 13 January 2015 CONTEXT AND POLICY ISSUES According to the World health Organization, the
More informationTITLE: Computed Tomography: A Review of the Risk of Cancer Associated with Radiation Exposure
TITLE: Computed Tomography: A Review of the Risk of Cancer Associated with Radiation Exposure DATE: 18 August 2009 CONTEXT AND POLICY ISSUES: Health care professionals order diagnostic imaging for their
More informationInnovation In Transplantation:
Innovation In Transplantation: Improving outcomes Thomas C. Pearson Department of Surgery Emory Transplant Center CHOA Symposium October 22, 2016 Disclosures Belatacept preclinical and clinical trial were
More informationService Line: Rapid Response Service Version: 1.0 Publication Date: January 21, 2019 Report Length: 5 Pages
CADTH RAPID RESPONSE REPORT: REFERENCE LIST Topical Cantharidin/ Salicylic Acid/ Podophyllin for the Treatment of Warts: Clinical Effectiveness and Guidelines Service Line: Rapid Response Service Version:
More informationTitle: Non-Steroidal Anti-Inflammatory Drugs for Analgesia in Patients with Fracture: Evidence for Use
Title: Non-Steroidal Anti-Inflammatory Drugs for Analgesia in Patients with Fracture: Evidence for Use Date: 03 June 2008 Context and policy issues: In 2000-2001, 3.4 million Canadians aged 12 years or
More informationBetter than Google- Click on Immunosuppression Renal Transplant. David Landsberg Oct
Better than Google- Click on Immunosuppression Renal Transplant David Landsberg Oct 3 2008 OUTLINE History of Immunosuppression Trends in Immunosupression FK vs CYA Steroid Minimization CNI Avoidance Sirolimus
More informationASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/381922/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER The Paediatric Working Party
More information1. What is the comparative efficacy of IV lorazepam and IV diazepam for the treatment of febrile seizures in children (less than 12 years of age)?
Title: The Use of Lorazepam for Febrile Seizures in Children Date: 25 January 2008 Context and policy issues: Febrile seizures are the most common form of childhood seizures, affecting approximately 2
More informationAmerican Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc.
American Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc. 2009 The Authors Journal compilation 2009 The American Society of Transplantation and the American Society of Transplant
More informationLiterature Review: Transplantation July 2010-June 2011
Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More informationWhat is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham
What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham SYMPHONY Study Ekberg et al. NEJM 2008 Excluded: DCD kidneys; CIT>30hours;
More informationTITLE: Crushed Buprenorphine or Buprenorphine-Naloxone for Opioid Dependency: A Review of the Clinical Effectiveness and Guidelines
TITLE: Crushed Buprenorphine or Buprenorphine-Naloxone for Opioid Dependency: A Review of the Clinical Effectiveness and Guidelines DATE: 18 July 2016 CONTEXT AND POLICY ISSUES Opioid dependence is a chronic
More informationFor Immediate Release Contacts: Jenny Keeney Astellas US LLC (847)
For Immediate Release Contacts: Jenny Keeney Astellas US LLC (847) 317-5405 Lauren McDonnell GolinHarris (312) 729-4233 ASTELLAS RECEIVES FDA APPROVAL FOR USE OF PROGRAF (TACROLIMUS) IN CONJUNCTION WITH
More informationDiltiazem use in tacrolimus-treated renal transplant recipients Kothari J, Nash M, Zaltzman J, Prasad G V R
Diltiazem use in tacrolimus-treated renal transplant recipients Kothari J, Nash M, Zaltzman J, Prasad G V R Record Status This is a critical abstract of an economic evaluation that meets the criteria for
More informationHealth technology Two prophylaxis schemes against organ rejection in renal transplantation were compared in the study:
An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation Polsky D, Weinfurt K P, Kaplan B, Kim J, Fastenau J, Schulman K A Record Status
More informationTransplantation in Australia and New Zealand
Transplantation in Australia and New Zealand Matthew D. Jose MBBS (Adel), FRACP, FASN, PhD (Monash), AFRACMA Professor of Medicine, UTAS Renal Physician, Royal Hobart Hospital Overview CKD in Australia
More informationPost Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H.
Post Transplant Immunosuppression: Consideration for Primary Care Sameh Abul-Ezz, M.D., Dr.P.H. Objectives Discuss the commonly used immunosuppressive medications and what you need to know to care for
More informationProteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation
Trends Fritz in Transplant. Diekmann: 2011;5:139-43 Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation
More informationTITLE: Shilla and MAGEC Systems for Growing Children with Scoliosis: A Review of the Clinical Benefits and Cost-Effectiveness
TITLE: Shilla and MAGEC Systems for Growing Children with Scoliosis: A Review of the Clinical Benefits and Cost-Effectiveness DATE: 17 January 2013 CONTEXT AND POLICY ISSUES Early-onset scoliosis (EOS)
More informationService Line: Rapid Response Service Version: 1.0 Publication Date: October 30, 2018 Report Length: 7 Pages
CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Topical Silver Nitrate for the Management of Hemostasis: A Review of Clinical Effectiveness, Cost- Effectiveness, and Guidelines Service Line:
More informationConsidering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol
Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol Patient details Name DOB ESRD Other history Mr. B.I.B. 12 January 1975 (34yo) Membranous GN
More informationCADTH Therapeutic Review
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Therapeutic Review August 2012 Volume 1, Issue 1A Antithrombotic Therapy for
More informationTITLE: Hypertonic Saline Nebules for Patients with Cystic Fibrosis and Bronchioectasis: A Review of the Clinical and Cost-Effectiveness
TITLE: Hypertonic Saline Nebules for Patients with Cystic Fibrosis and Bronchioectasis: A Review of the Clinical and Cost-Effectiveness DATE: 16 March 2009 CONTEXT AND POLICY ISSUES: Hypertonic saline
More informationBelatacept: An Update of Ongoing Clinical Trials
Belatacept: An Update of Ongoing Clinical Trials Michael D. Rizzari, MD University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin Abstract Belatacept is a fusion protein
More informationOrgan rejection is one of the serious
Original Article Outcomes of Late Corticosteroid Withdrawal after Renal Transplantation in Patients Exposed to Tacrolimus and/or Mycophenolate Mofetil: Meta-Analysis of Randomized Controlled Trials A.
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 30 November 2011 NULOJIX 250 mg, powder for concentrate for solution for infusion B/1 (CIP code: 580 415-7) B/2 (CIP
More informationImmunopathology of T cell mediated rejection
Immunopathology of T cell mediated rejection Ibrahim Batal MD Columbia University College of Physicians & Surgeons New York, NY, USA Overview Pathophysiology and grading of TCMR TCMR is still a significant
More informationCase Report Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate
Case Reports in Transplantation, Article ID 190516, 4 pages http://dx.doi.org/10.1155/2014/190516 Case Report Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationTITLE: Levothyroxine for Solid Organ Donors: A Review of the Clinical-Effectiveness and Guidelines
TITLE: Levothyroxine for Solid Organ Donors: A Review of the Clinical-Effectiveness and Guidelines DATE: 20 May 2009 CONTEXT AND POLICY ISSUES: Organ transplantation is a life-saving treatment for patients
More informationTable S1. Clinical outcomes of the acceptable mismatch allocation model.
Table S1. Clinical outcomes of the acceptable mismatch allocation model. Recipient Age PRA Waiting Time (months) HLA mismatch (A/B/DR) HLAMatchmaker acceptable mismatch (years) (%) Actual Simulation Change
More informationThis report will provide a review on the comparative clinical effectiveness and safety between intranasal triamcinolone and beclomethasone.
TITLE: Intranasal Triamcinolone versus Intranasal Beclomethasone for Acute and Chronic Sinus Inflammation: A Review of Comparative Clinical Effectiveness and Safety DATE: 29 January 2013 CONTEXT AND POLICY
More informationHealth Interventions in Ambulatory Cancer Care Centres DRAFT. Objectives. Methods
ENVIRONMENTAL SCAN Health Interventions in Ambulatory Cancer Care Centres Context Cancer, a complex, chronic condition, will affect an estimated two in five Canadians in their lifetime. 1 Cancer requires
More informationKidney Dysfunction in the Recipients of Liver Transplants
Kidney Dysfunction in the Recipients of Liver Transplants Alan Wilkinson and Phuong-Thu Pham Key Points 1. Pretransplant kidney function is an important predictor of posttransplant kidney function. 2.
More informationLiterature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
More informationReduced graft function (with or without dialysis) vs immediate graft function a comparison of long-term renal allograft survival
Nephrol Dial Transplant (2006) 21: 2270 2274 doi:10.1093/ndt/gfl103 Advance Access publication 22 May 2006 Original Article Reduced graft function (with or without dialysis) vs immediate graft function
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2014 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE II TRANSPLANTATION Section
More informationService Line: Rapid Response Service Version: 1.0 Publication Date: June 12, 2018 Report Length: 5 Pages
CADTH RAPID RESPONSE REPORT: SUMMARY OF ABSTRACTS Sensory Rooms for Pediatric Patients with Neurocognitive Disorders: Clinical Effectiveness and Guidelines Service Line: Rapid Response Service Version:
More informationChronic Kidney Disease (CKD) Stages. CHRONIC KIDNEY DISEASE Treatment Options. Incident counts & adjusted rates, by primary diagnosis Figure 2.
Chronic Kidney Disease (CKD) Stages Stage 1 GFR > 90 (evidence of renal disease) Stage 2 GFR 60-89 Stage 3 GFR 30-59 Stage 4 GFR 15-29 Stage 5 GFR
More informationTITLE: Universal, Community-Based Developmental Screening Tools for Children 6 Years and Younger: A Review of Clinical Effectiveness
TITLE: Universal, Community-Based Developmental Screening Tools for Children 6 Years and Younger: A Review of Clinical Effectiveness DATE: 23 September 2009 CONTEXT AND POLICY ISSUES: Universal, community-based
More informationSupporting a Pediatric Investigational Plan for Everolimus - Defining the extrapolation plan
Supporting a Pediatric Investigational Plan for Everolimus - Defining the extrapolation plan Thomas Dumortier, Mick Looby Novartis Pharma AG, Basel, Switzerland EMA public workshop on extrapolation of
More informationService Line: Rapid Response Service Version: 1.0 Publication Date: March 5, 2018 Report Length: 5 Pages
CADTH RAPID RESPONSE REPORT: REFERENCE LIST Oral Neomycin in Preparation for Colorectal Procedures: Clinical Effectiveness, Cost- Effectiveness and Guidelines Service Line: Rapid Response Service Version:
More informationChronic Kidney Disease & Transplantation. Paediatrics : 2004 FRACP
Chronic Kidney Disease & Transplantation Paediatrics : 2004 FRACP ANZDATA Registry Mode of First Treatment - Paediatric 14 12 10 8 6 4 2 0 0-4 y 5-9 y 10-14 y 15-19 y Hospital CAPD Hospital HD Hospital
More informationService Line: Rapid Response Service Version: 1.0 Publication Date: July 09, 2018 Report Length: 7 Pages
CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Eltrombopag for the treatment of Aplastic Anemia: A Review of Clinical and Cost-Effectiveness Service Line: Rapid Response Service Version:
More informationBK Virus (BKV) Management Guideline: July 2017
BK Virus (BKV) Management Guideline: July 2017 BK virus has up to a 60-80% seroprevalence rate in adults due to a primary oral or respiratory exposure in childhood. In the immumocompromised renal transplant
More informationMyfortic Transplant Coordinator Survey: Defining the perceptions of generic mycophenolate mofetil
Myfortic Transplant Coordinator Survey: Defining the perceptions of generic mycophenolate mofetil July 28, 2010 Prepared for: Steve Arcona, PhD Director, Outcomes Research Novartis Pharmaceuticals Corporation
More informationREACH Risk Evaluation to Achieve Cardiovascular Health
Dyslipidemia and transplantation History: An 8-year-old boy presented with generalized edema and hypertension. A renal biopsy confirmed a diagnosis of focal segmental glomerulosclerosis (FSGS). After his
More informationTITLE: Exercise in Patients with Chronic Kidney Disease and Kidney Transplant: A Review of the Clinical and Cost-Effectiveness
TITLE: Exercise in Patients with Chronic Kidney Disease and Kidney Transplant: A Review of the Clinical and Cost-Effectiveness DATE: 27 November 2008 CONTEXT AND POLICY ISSUES: Chronic kidney disease (CKD)
More informationGeneral Introduction. 1 general introduction 13
General Introduction In The Netherlands 13,000 patients suffer from end stage renal disease (ESRD), which left untreated inevitably results in death. Every year this number increases with approximately
More information